New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePT-141 (Bremelanotide) vs Cerebrolysin

PT-141 (Bremelanotide) vs Cerebrolysin

Side-by-side comparison of key properties, dosing, and research.

Sexual Health & Libido
PT-141 (Bremelanotide)
Cognitive EnhancementAnti-Aging & Longevity
Cerebrolysin
Summary
PT-141 (Bremelanotide) is a cyclic peptide melanocortin receptor agonist that enhances sexual desire and arousal through central nervous system mechanisms. It is FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD).
Cerebrolysin is a porcine brain-derived neuropeptide complex that mimics the action of endogenous neurotrophic factors (BDNF, NGF, GDNF, NT-3). It promotes neurogenesis, neuroprotection, and synaptic plasticity, and is approved in many countries for stroke, traumatic brain injury, and Alzheimer's disease.
Half-Life
2–3 hours
Variable for the complex; individual peptide fractions: minutes to hours
Admin Route
SubQ
IV, IM
Research
Typical Dose
0.5–1.75 mg
5–10 mL
Frequency
As needed (not daily)
Daily for 10–20 days
Key Benefits
  • Enhances sexual desire and libido in both men and women
  • Improves arousal through central nervous system activation
  • Effective for psychological erectile dysfunction
  • Works for female sexual arousal disorder
  • May improve sexual satisfaction and intensity
  • Fast-acting — effects within 45–60 minutes
  • FDA-approved for HSDD in premenopausal women
  • Promotes neurogenesis and synaptic plasticity
  • Approved for stroke rehabilitation (accelerates recovery)
  • Alzheimer's disease: slows progression and improves cognition
  • Traumatic brain injury recovery
  • Enhances memory and executive function
  • Neuroprotection against oxidative stress and excitotoxicity
  • Anti-amyloid and anti-tau effects
  • Mood improvement and reduced anxiety
Side Effects
  • Nausea (most common — 40% of users in clinical trials)
  • Facial flushing and warmth
  • Transient blood pressure changes (typically increase then normalize)
  • Headache
  • +2 more
  • Generally well tolerated
  • Mild nausea and dizziness (IV infusion)
  • Headache at initiation
  • Rare: agitation (usually at very high doses)
  • +2 more
Stacks With